A recent study demonstrated that the cuproptosis-related gene FDX1 plays an essential role in the prognosis of HCC and successfully developed a cuproptosis-related risk score that can predict the efficiency of sorafenib and the non-responsiveness to transcatheter arterial chemoembolization in HCC patients [9]. Here, FDX1 is linked to hepatocellular carcinoma.